Albany Molecular Research, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Albany Molecular Research, Inc.
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Founded with a vision to change point-of-care diagnostics, Osler Diagnostics has raised nearly $200m to develop and commercialize a platform that promises to revolutionize diagnostics with just a drop of a patients’ blood.
- Contract Research, Toxicology Testing-CRO
- Laboratory Testing Services
- Generic Drugs
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Cedarburg Pharmaceuticals, Inc.
- Excelsyn Ltd.
- Hyaluron Inc.
- Gadea Pharmaceutical Group (Crystal Pharma)
- Prime European Therapeuticals S.p.A. (Euticals)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.